Table 1:

Analysis of 15 trials including 759 dogs treated with ciclosporin for canine atopic dermatitis

TotalFontaine and Olivry 2001Iwasaki and others 2002Olivry and others 2002aOlivry and others 2002bSteffan and others 2003Olivry and others 2003Burton and others 2004Bensignor and Guaguère 2004Steffan and others 2005Thelen and others 2006Carlotti and others 2009Nuttall and others 2012Kovalik and others 2011a*Kovalik and others 2012Dip and others 2013
Number (%) of dogs7591492611511730411526625821131625
Vomiting26%2 (14)10 (11)23 (38)1 (7)43 (37)6 (20)4 (10)5 (33)82 (31)006 (29)3 (23)2 (13)10 (40)
Soft stools/diarrhoea15%013 (14)21 (34)3 (20)6 (5)04 (10)053 (20)002 (10)2 (15)5 (31)5 (20)
Miscellaneous3%0001 (7)10 (9)1 (3)00010 (40)00002 (8)
Loss of appetite2%01 (1)005 (4)0008 (3)001 (5)000
Nodules/cyst1%00007 (6)0003 (1)000000
Urinary tract infection1%0000000010 (4)000000
Gingival hyperplasia1%00003 (3)0006 (2)000000
Lethargy/lameness1%0001 (7)0001 (7)6 (2)000001 (4)
Reproductive 1%00007 (6)0000000000
Papillomatosis1%0001 (7)01 (3)004 (2)000001 (4)
Lymphadenopathy0.8%000000006 (2)000000
Neurological0.8%000000004 (2)1 (4)00001 (4)
Other urine abnormalities0.3%000000000000002 (8)
Urticaria/angio-oedema0.3%0001 (7)01 (3)000000000
ADR requiring cessation of therapy5%05 (5)02 (13)10 (9)5 (17)0011 (4)3 (12)00000
Total59.2%14%31%72%68%79%46%20%40%73%56%0%44%38%44%88%
  • * All the trials used 5 mg/kg ciclosporin as Atopica (Novartis Animal Health) except Kovalik and others 2011a, which used 5 mg/kg ciclosporin as Equoral oral solution (Teva Pharmaceuticals)

  • ADR Adverse drug reaction